This patient (male, 19 years, primary hepatic manifestation) with worsening of liver disease experienced increasing transaminases (AST/ALT U/L) from Baseline (25/53 U/L) to 6 months (54/181 U/L) and 12 months (63/217 U/L) follow‐up without impairment of liver synthesis or neurological worsening. This evidence concerns the gene GPT and liver disorder.